Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Obesity

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 78 articles: HTML format

Single Articles

April 2024
1. KOSIBOROD MN, Petrie MC, Borlaug BA, Butler J, et al
   Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
   N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2313917.
   PubMed     Abstract available
   
   
   February 2024
2. LINCOFF AM, Ryan DH, Esbjerg S
   Semaglutide and Cardiovascular Outcomes. Reply.
   N Engl J Med. 2024;390:768-769.
   PubMed    
   
   
   
3. NEVES JS, Leite AR, Ferreira JP
   Semaglutide and Cardiovascular Outcomes.
   N Engl J Med. 2024;390:767-768.
   PubMed    
   
   
   
4. CAMPBELL LA, Jenkins AV, Jackson CD
   Semaglutide and Cardiovascular Outcomes.
   N Engl J Med. 2024;390:767.
   PubMed    
   
   
   
5. BELKHOURIBCHIA J
   Semaglutide and Cardiovascular Outcomes.
   N Engl J Med. 2024;390:767.
   PubMed    
   
   
   
6. BELALCAZAR LM, Kuo YF
   Semaglutide and Cardiovascular Outcomes.
   N Engl J Med. 2024;390:766-767.
   PubMed    
   
   
   
7. TAQUETI VR, Shaw LJ
   Semaglutide and Cardiovascular Outcomes.
   N Engl J Med. 2024;390:766.
   PubMed    
   
   
   
8. GORTMAKER SL, Bleich SN, Williams DR
   Childhood Obesity Prevention - Focusing on Population-Level Interventions and Equity.
   N Engl J Med. 2024;390:681-683.
   PubMed    
   
   
   
9. GOLOVATY I, Hagan S
   Direct-to-Consumer Platforms for New Antiobesity Medications - Concerns and Potential Opportunities.
   N Engl J Med. 2024;390:677-680.
   PubMed    
   
   
   December 2023
10. KOSIBOROD MN, Borlaug BA, Petrie MC
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity. Reply.
    N Engl J Med. 2023;389:2398-2399.
    PubMed    
    
    
    
11. O'DOWLING R
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    
    
    
    
12. WAGNER J
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    
    
    
    
13. GAO Y, Gao Y, Qiu H
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2397-2398.
    PubMed    
    
    
    
14. WHARTON S, Konig M
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
    N Engl J Med. 2023;389:2304-2305.
    PubMed    
    
    
    
15. POURKARIM F, Entezari-Maleki T
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303-2304.
    PubMed    
    
    
    
16. PRESTON W
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303.
    PubMed    
    
    
    November 2023
17. LINCOFF AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563.
    PubMed     Abstract available
    
    
    
18. KHERA A, Powell-Wiley TM
    SELECTing Treatments for Cardiovascular Disease - Obesity in the Spotlight.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMe2312646.
    PubMed    
    
    
    October 2023
19. JASTREBOFF AM, Kaplan LM, Hartman ML
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
    N Engl J Med. 2023;389:1629-1630.
    PubMed    
    
    
    
20. ELFEKI MA, Alkhouri N
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
    N Engl J Med. 2023;389:1629.
    PubMed    
    
    
    
21. BISSON A, Fauchier G, Fauchier L
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
    N Engl J Med. 2023;389:1628.
    PubMed    
    
    
    
22. HANNON TS, Arslanian SA
    Obesity in Adolescents. Reply.
    N Engl J Med. 2023;389:1344.
    PubMed    
    
    
    
23. BHOWMIK S, Mahapatra HS
    Obesity in Adolescents.
    N Engl J Med. 2023;389:1343-1344.
    PubMed    
    
    
    
24. ABU DAYYEH B, Stier C
    Obesity in Adolescents.
    N Engl J Med. 2023;389:1343.
    PubMed    
    
    
    August 2023
25. 
    Obesity and Heart Failure.
    N Engl J Med. 2023;389:e15.
    PubMed    
    
    
    
26. KOSIBOROD MN, Abildstrom SZ, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963.
    PubMed     Abstract available
    
    
    
27. PATTI ME
    Triple G Agonists - A Home Run for Obesity?
    N Engl J Med. 2023;389:562-563.
    PubMed    
    
    
    July 2023
28. HANNON TS, Arslanian SA
    Obesity in Adolescents.
    N Engl J Med. 2023;389:251-261.
    PubMed    
    
    
    June 2023
29. JASTREBOFF AM, Kaplan LM, Frias JP, Wu Q, et al
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
    N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972.
    PubMed     Abstract available
    
    
    
30. WHARTON S, Blevins T, Connery L, Rosenstock J, et al
    Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023 Jun 23. doi: 10.1056/NEJMoa2302392.
    PubMed     Abstract available
    
    
    
31. STOOPS H, Dar M
    Equity and Obesity Treatment - Expanding Medicaid-Covered Interventions.
    N Engl J Med. 2023;388:2309-2311.
    PubMed    
    
    
    
32. ROSEN CJ
    Antagonizing the Leptin Receptor in Obesity.
    N Engl J Med. 2023;388:2291-2293.
    PubMed    
    
    
    
33. FUNCKE JB, Moepps B, Roos J, von Schnurbein J, et al
    Rare Antagonistic Leptin Variants and Severe, Early-Onset Obesity.
    N Engl J Med. 2023;388:2253-2261.
    PubMed     Abstract available
    
    
    March 2023
34. WEGHUBER D, Kelly AS, Arslanian S
    Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
    N Engl J Med. 2023;388:1146.
    PubMed    
    
    
    
35. MALOZOWSKI S
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145-1146.
    PubMed    
    
    
    
36. SNAITH JR, Greenfield JR
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145.
    PubMed    
    
    
    November 2022
37. WEGHUBER D, Barrett T, Barrientos-Perez M, Gies I, et al
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2022 Nov 2. doi: 10.1056/NEJMoa2208601.
    PubMed     Abstract available
    
    
    October 2022
38. JASTREBOFF AM, Aronne LJ, Stefanski A
    Tirzepatide Once Weekly for the Treatment of Obesity. Reply.
    N Engl J Med. 2022;387:1434-1435.
    PubMed    
    
    
    
39. VENNIYOOR A
    Tirzepatide Once Weekly for the Treatment of Obesity.
    N Engl J Med. 2022;387:1433-1434.
    PubMed    
    
    
    
40. HAGERICH K, Durkee M, Goldstein MG
    Tirzepatide Once Weekly for the Treatment of Obesity.
    N Engl J Med. 2022;387:1433.
    PubMed    
    
    
    
41. DEKKER TJA
    Tirzepatide Once Weekly for the Treatment of Obesity.
    N Engl J Med. 2022;387:1433.
    PubMed    
    
    
    
42. CREANGA AA, Catalano PM, Bateman BT
    Obesity in Pregnancy. Reply.
    N Engl J Med. 2022;387:1339.
    PubMed    
    
    
    
43. HENDERSON JL, Eke AC
    Obesity in Pregnancy.
    N Engl J Med. 2022;387:1338-1339.
    PubMed    
    
    
    
44. ZHOU H, Liu X, Li W
    Obesity in Pregnancy.
    N Engl J Med. 2022;387:1338.
    PubMed    
    
    
    September 2022
45. KUHNEN P, Clement K
    Long-Term MC4R Agonist Treatment in POMC-Deficient Patients.
    N Engl J Med. 2022;387:852-854.
    PubMed    
    
    
    August 2022
46. BRAMANTE CT, Huling JD, Tignanelli CJ, Buse JB, et al
    Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
    N Engl J Med. 2022;387:599-610.
    PubMed     Abstract available
    
    
    July 2022
47. DE OLIVEIRA EM, Keogh JM, Farooqi IS
    Obesity-Associated GNAS Mutations and the Melanocortin Pathway. Reply.
    N Engl J Med. 2022;387:285-286.
    PubMed    
    
    
    
48. KLEINENDORST L, Boon E, van Haelst MM
    Obesity-Associated GNAS Mutations and the Melanocortin Pathway.
    N Engl J Med. 2022;387:285.
    PubMed    
    
    
    
49. OKUBO J, Mancini MC, de Melo ME
    Obesity-Associated GNAS Mutations and the Melanocortin Pathway.
    N Engl J Med. 2022;387:284.
    PubMed    
    
    
    
50. POON KS, Tan KM
    Obesity-Associated GNAS Mutations and the Melanocortin Pathway.
    N Engl J Med. 2022;387:284.
    PubMed    
    
    
    
51. CREANGA AA, Catalano PM, Bateman BT
    Obesity in Pregnancy.
    N Engl J Med. 2022;387:248-259.
    PubMed    
    
    
    June 2022
52. JASTREBOFF AM, Aronne LJ, Ahmad NN, Wharton S, et al
    Tirzepatide Once Weekly for the Treatment of Obesity.
    N Engl J Med. 2022 Jun 4. doi: 10.1056/NEJMoa2206038.
    PubMed     Abstract available
    
    
    
53. ROSEN CJ, Ingelfinger JR
    Shifting Tides Offer New Hope For Obesity.
    N Engl J Med. 2022 Jun 4. doi: 10.1056/NEJMe2206939.
    PubMed    
    
    
    April 2022
54. LIU D, Huang Y, Huang C, Yang S, et al
    Calorie Restriction with or without Time-Restricted Eating in Weight Loss.
    N Engl J Med. 2022;386:1495-1504.
    PubMed     Abstract available
    
    
    February 2022
55. CYPESS AM
    Reassessing Human Adipose Tissue.
    N Engl J Med. 2022;386:768-779.
    PubMed    
    
    
    December 2021
56. HAGAN S
    E66.01 and Our Culture of Shame.
    N Engl J Med. 2021;385:2307-2309.
    PubMed    
    
    
    October 2021
57. JUPPNER H
    Obesity and Galphas Variants.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMe2113123.
    PubMed    
    
    
    
58. MENDES DE OLIVEIRA E, Keogh JM, Talbot F, Henning E, et al
    Obesity-Associated GNAS Mutations and the Melanocortin Pathway.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2103329.
    PubMed     Abstract available
    
    
    August 2021
59. JENSEN SBK, Torekov SS
    Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. Reply.
    N Engl J Med. 2021;385:573-574.
    PubMed    
    
    
    
60. OKECHUKWU CE
    Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    N Engl J Med. 2021;385:572-573.
    PubMed    
    
    
    
61. DE SOUTO BARRETO P, Rolland Y
    Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    N Engl J Med. 2021;385:572.
    PubMed    
    
    
    July 2021
62. ROSEN CJ, Ingelfinger JR
    Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply.
    N Engl J Med. 2021;385:e4.
    PubMed    
    
    
    
63. WILDING JPH, Calanna S, Kushner RF
    Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply.
    N Engl J Med. 2021;385:e4.
    PubMed    
    
    
    
64. SRIVASTAVA G, Kumar RB
    Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2021;385:e4.
    PubMed    
    
    
    
65. NADOLSKY KZ, Agarwal M
    Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2021;385:e4.
    PubMed    
    
    
    
66. KHOO TK, Lin J
    Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2021;385:e4.
    PubMed    
    
    
    
67. JAVOR E, Lucijanic M, Skelin M
    Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2021;385:e4.
    PubMed    
    
    
    June 2021
68. WU JM
    Stress Incontinence in Women.
    N Engl J Med. 2021;384:2428-2436.
    PubMed    
    
    
    May 2021
69. LUNDGREN JR, Janus C, Jensen SBK, Juhl CR, et al
    Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    N Engl J Med. 2021;384:1719-1730.
    PubMed     Abstract available
    
    
    March 2021
70. RATHMELL JC
    Obesity, Immunity, and Cancer.
    N Engl J Med. 2021;384:1160-1162.
    PubMed    
    
    
    
71. INGELFINGER JR, Rosen CJ
    STEP 1 for Effective Weight Control - Another First Step?
    N Engl J Med. 2021;384:1066-1067.
    PubMed    
    
    
    February 2021
72. WILDING JPH, Batterham RL, Calanna S, Davies M, et al
    Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2021 Feb 10. doi: 10.1056/NEJMoa2032183.
    PubMed     Abstract available
    
    
    January 2021
73. CARLSSON LMS, Jacobson P, Peltonen M
    Life Expectancy after Bariatric Surgery - the Swedish Obese Subjects Study. Reply.
    N Engl J Med. 2021;384:89.
    PubMed    
    
    
    
74. GILLION V, Demoulin N, Devresse A
    Life Expectancy after Bariatric Surgery - the Swedish Obese Subjects Study.
    N Engl J Med. 2021;384:88.
    PubMed    
    
    
    
75. TAGLIABUE E, Ceriani V, Pontiroli AE
    Life Expectancy after Bariatric Surgery - the Swedish Obese Subjects Study.
    N Engl J Med. 2021;384:88.
    PubMed    
    
    
    December 2020
76. KUMANYIKA S, Dietz WH
    Solving Population-wide Obesity - Progress and Future Prospects.
    N Engl J Med. 2020;383:2197-2200.
    PubMed    
    
    
    November 2020
77. LU KH, Broaddus RR
    Endometrial Cancer.
    N Engl J Med. 2020;383:2053-2064.
    PubMed    
    
    
    October 2020
78. CARLSSON LMS, Sjoholm K, Jacobson P, Andersson-Assarsson JC, et al
    Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study.
    N Engl J Med. 2020;383:1535-1543.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Obesity is free of charge.